
Sign up to save your podcasts
Or


In this week's episode, we explore the quest for a therapy that not only alleviates symptoms of osteoarthritis but also addresses the underlying disease process. Host Professor David Hunter is joined by Chris Knight and Dr Sandeep Basnet from Formation Bio to discuss the complexities and breakthroughs in developing disease-modifying osteoarthritis drugs (DMOADs).
They dive into the challenges of clinical trials, the high stakes of drug development, and the promising future of AI in revolutionising this field.
Tune in to learn how close we are to seeing these game-changing therapies become a reality and what it could mean for millions living with osteoarthritis.
RESOURCES
Formation Bio: https://www.formation.bio/
CONNECT WITH US
Hosted on Acast. See acast.com/privacy for more information.
By David Hunter, PhD, FRACP (Rheum)4.9
2424 ratings
In this week's episode, we explore the quest for a therapy that not only alleviates symptoms of osteoarthritis but also addresses the underlying disease process. Host Professor David Hunter is joined by Chris Knight and Dr Sandeep Basnet from Formation Bio to discuss the complexities and breakthroughs in developing disease-modifying osteoarthritis drugs (DMOADs).
They dive into the challenges of clinical trials, the high stakes of drug development, and the promising future of AI in revolutionising this field.
Tune in to learn how close we are to seeing these game-changing therapies become a reality and what it could mean for millions living with osteoarthritis.
RESOURCES
Formation Bio: https://www.formation.bio/
CONNECT WITH US
Hosted on Acast. See acast.com/privacy for more information.

107 Listeners

123 Listeners

51 Listeners

847 Listeners

15 Listeners

76 Listeners

132 Listeners

644 Listeners

2,636 Listeners

253 Listeners

90 Listeners

418 Listeners

252 Listeners

37 Listeners

2,085 Listeners